GH Secretagogues
CJC-1295 DAC
← Back to Library
Protocol not independently verified FDA safety flag GH Axis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 2, 5, 10 mg
Dosing window: Anytime
Receptor / target: GHRH
Properties: GH Secretagogue
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 300 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 3-4 | 500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 5-6 | 750 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 7-8 | 1000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 9-10 | 1250 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 11-12 | 1500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 13-14 | 1750 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 15-16 | 2000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative Titration 1
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 5-8 | 1000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 9-12 | 1500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 13-16 | 2000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 2
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 3-4 | 750 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 5-6 | 1000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 7-8 | 1250 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 9-10 | 1500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 11-12 | 2000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 13-14 | 2500 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
| Weeks 15-16 | 3000 mcg | Administer 2x Weekly (e.g., Sun/Weds, Mon/Thurs, or Tues/Fri). |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Anytime. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.
Independent evidence
Independent safety notes: FDA lists CJC-1295 among withdrawn nominated bulk substances with potential significant safety risks, limited clinical data, and serious adverse events reported.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active cancer or history of malignancy: sustained GH and IGF-1 elevation accelerates cell proliferation; contraindicated in any actively growing tumor.
- High risk of tumor growth: subjects with pre-cancerous conditions or elevated cancer biomarkers.
- Active acromegaly or conditions involving excess endogenous GH or IGF-1: additive hypersomatotrophism.
- Uncontrolled diabetes mellitus or significant insulin resistance: continuous GH elevation meaningfully increases insulin resistance; DAC's persistent hormonal profile is more problematic than pulsatile approaches.
- Diabetic ketoacidosis.
- Disruption of the hypothalamic-pituitary axis: pituitary adenoma, cranial radiation history, or post-surgical pituitary dysfunction.
- Concurrent use with CJC-1295 No DAC, sermorelin, tesamorelin, or HGH 191aa: direct GHRH receptor competition or redundant GH axis overstimulation.
- Concomitant high-dose glucocorticoid therapy: blunts pituitary GH response and inhibits IGF-1.
- Severe carpal tunnel syndrome: GH-mediated fluid retention worsens median nerve compression.
- Pregnancy: safety not established.
- Breastfeeding: safety not established.
- Known hypersensitivity to CJC-1295 DAC or any formulation excipients.
- Pediatric use in children with closed growth plates.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Water retention and peripheral edema: the most frequently reported adverse effect; GH-mediated sodium and fluid retention is more persistent and pronounced with DAC than with No DAC due to continuous GH elevation.
- Head rush and transient facial flushing: present but typically milder than with No DAC due to the absence of a sharp GH peak.
- Joint stiffness and arthralgia: GH-mediated periarticular fluid accumulation; common, particularly in wrists, hands, and knees.
- Tingling or numbness in extremities (paresthesia): from GH-related fluid shifts compressing peripheral nerves.
- Carpal tunnel syndrome: sustained GH elevation can produce or exacerbate median nerve compression.
- Fatigue or lethargy: more diffuse than with No DAC; related to sustained rather than pulsatile GH effects.
- Headache: less acute than No DAC but present.
- Increased appetite: modest orexigenic GH effects.
- Vivid dreams: GH elevation during sleep phases.
- Insulin resistance: continuous rather than pulsatile GH exposure has more significant impact on insulin sensitivity; monitor fasting glucose, particularly in subjects with metabolic risk factors.
- Elevated fasting blood glucose: secondary to GH-mediated insulin resistance; monitor throughout cycle.
- Pituitary downregulation: risk with DAC is somewhat higher than No DAC due to continuous GHRH-R stimulation; strict 4-week washout is required.
- Slow side effect clearance post-cycle: albumin-bound DAC depot persists for 2+ weeks after the last injection; side effects do not resolve immediately upon stopping.
- Injection site irritation: localized redness, swelling, or discomfort.
- Antibody formation: rare; small percentage of subjects may develop anti-peptide antibodies with long-cycle use.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
- PubMed search: CJC-1295 DAC